Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Other Accumulated Expenses of $310000.0 for Q1 2026, down 80.27% year-on-year from $1.6 million in Q1 2025, and down 84.91% on a QoQ basis from $2.1 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Other Accumulated Expenses data on file, last reported at $310000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 80.27% year-over-year to $310000.0; the trailing twelve-month figure through Mar 2026 stood at $310000.0 (down 80.27% YoY), and the FY2025 full-year result was $405000.0, down 86.88% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $310000.0, down from $2.1 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $6.9 million in Q4 2022 and bottomed at $310000.0 in Q1 2026.
- The 5-year median for Other Accumulated Expenses is $1.6 million (2025), against an average of $2.6 million.
- The widest annual swing landed in 2022, when Other Accumulated Expenses jumped 541.91%; it then tumbled 86.88% in 2025.
- A 5-year view of Other Accumulated Expenses shows it stood at $6.9 million in 2022, then sank by 63.76% to $2.5 million in 2023, then sank by 41.7% to $1.4 million in 2024, then jumped by 41.66% to $2.1 million in 2025, then plunged by 84.91% to $310000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $310000.0 (Q1 2026), $2.1 million (Q4 2025), and $405000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 310,000.00 |
| Dec 31, 2025 | 2.05 Mn |
| Sep 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 969,000.00 |
| Mar 31, 2025 | 1.57 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 2.49 Mn |
| Sep 30, 2023 | 6.12 Mn |
| Jun 30, 2023 | 5.70 Mn |
| Mar 31, 2023 | 867,000.00 |
| Dec 31, 2022 | 6.86 Mn |
| Sep 30, 2022 | 5.53 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 6.06 Mn |
| Jun 30, 2021 | 1.06 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 890,000.00 |
| Sep 30, 2020 | 612,000.00 |
| Jun 30, 2020 | 4.78 Mn |
| Mar 31, 2020 | 640,000.00 |
| Dec 31, 2019 | 3.88 Mn |
| Sep 30, 2019 | 6.94 Mn |
| Jun 30, 2019 | 688,000.00 |
| Mar 31, 2019 | 920,000.00 |
| Dec 31, 2018 | 1.04 Mn |
| Sep 30, 2018 | 593,000.00 |
| Jun 30, 2018 | 365,000.00 |
| Mar 31, 2018 | 426,000.00 |
| Dec 31, 2017 | 405,000.00 |
| Sep 30, 2017 | 399,000.00 |
| Jun 30, 2017 | 442,000.00 |
| Mar 31, 2017 | 504,000.00 |
| Dec 31, 2016 | 403,000.00 |
| Sep 30, 2016 | 304,000.00 |
| Jun 30, 2015 | 345,000.00 |
| Mar 31, 2015 | 623,000.00 |
| Dec 31, 2014 | 312,000.00 |
| Sep 30, 2014 | 312,000.00 |
| Jun 30, 2014 | 348,000.00 |
| Mar 31, 2014 | 225,000.00 |
| Dec 31, 2013 | 523,000.00 |
| Sep 30, 2013 | 387,000.00 |
| Jun 30, 2013 | 437,000.00 |
| Mar 31, 2013 | 592,000.00 |
| Sep 30, 2012 | 291,000.00 |